Dr. Peter R. Seidensticker, MD - Vice President MCA, Modality Head CT / CV & Informatics - Bayer Pharmaceuticals | LinkedIn
![Max SEIDENSTICKER | Senior Physician | Otto-von-Guericke-Universität Magdeburg, Magdeburg | OvGU | Clinic for Radiology and Nuclear Medicine Max SEIDENSTICKER | Senior Physician | Otto-von-Guericke-Universität Magdeburg, Magdeburg | OvGU | Clinic for Radiology and Nuclear Medicine](https://www.researchgate.net/publication/357605597/figure/fig2/AS:1109001827811331@1641418048702/Overall-survival-of-patients-with-ETS-20-vs-ETS-20-CI-confidence-interval-ETS_Q320.jpg)
Max SEIDENSTICKER | Senior Physician | Otto-von-Guericke-Universität Magdeburg, Magdeburg | OvGU | Clinic for Radiology and Nuclear Medicine
Dr. Peter R. Seidensticker, MD - Vice President MCA, Modality Head CT / CV & Informatics - Bayer Pharmaceuticals | LinkedIn
![PDF) Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib PDF) Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib](https://i1.rgstatic.net/publication/357605597_Early_tumor_shrinkage_and_response_assessment_according_to_mRECIST_predict_overall_survival_in_hepatocellular_carcinoma_patients_under_sorafenib/links/61d60d35e669ee0f5c8a4859/largepreview.png)
PDF) Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib
![Max SEIDENSTICKER | Senior Physician | Otto-von-Guericke-Universität Magdeburg, Magdeburg | OvGU | Clinic for Radiology and Nuclear Medicine Max SEIDENSTICKER | Senior Physician | Otto-von-Guericke-Universität Magdeburg, Magdeburg | OvGU | Clinic for Radiology and Nuclear Medicine](https://www.researchgate.net/publication/357605597/figure/fig1/AS:1109001827811330@1641418048623/Overall-survival-of-patients-with-compared-to-patients-without-objective-response-CI_Q320.jpg)